Ovid Therapeutics Inc (OVID) Actualités

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and...

Form 8-K - Current report

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30...

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Form 8-K - Current report

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report